Cambridge Investment Research Advisors’s Dimensional Ultrashort Fixed Income ETF DUSB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.27M Buy
25,006
+66
+0.3% +$3.35K ﹤0.01% 2078
2026
Q1
$1.26M Sell
24,940
-13,308
-35% -$675K ﹤0.01% 1962
2025
Q4
$1.94M Buy
38,248
+10,424
+37% +$529K 0.01% 1545
2025
Q3
$1.41M Sell
27,824
-3,314
-11% -$168K ﹤0.01% 1778
2025
Q2
$1.58M Buy
31,138
+10,669
+52% +$541K ﹤0.01% 1607
2025
Q1
$1.04M Buy
20,469
+15,679
+327% +$795K ﹤0.01% 1845
2024
Q4
$242K Buy
+4,790
New +$243K ﹤0.01% 3022

Other funds holding DUSB

Cambridge Investment Research Advisors's DUSB Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Dimensional Ultrashort Fixed Income ETF (DUSB) stake by 0.26% in Q2 2026, buying an estimated $3.35K and bringing the position to 25,006 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Cambridge Investment Research Advisors first reported a position in DUSB in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.94M in Q4 2025. 185 funds tracked by Wall St. Rank hold DUSB as of Q2 2026.

  • Cambridge Investment Research Advisors held 25,006 shares of Dimensional Ultrashort Fixed Income ETF worth $1.27M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 66 Dimensional Ultrashort Fixed Income ETF shares in Q2 2026, an estimated $3.35K.
  • Dimensional Ultrashort Fixed Income ETF made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2078 holding.
  • Cambridge Investment Research Advisors first reported a position in Dimensional Ultrashort Fixed Income ETF in Q4 2024 and has held it in 7 quarters since.
  • Cambridge Investment Research Advisors's Dimensional Ultrashort Fixed Income ETF position peaked at $1.94M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Dimensional Ultrashort Fixed Income ETF as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.